Life Sciences team aids Astellas Pharma in transfer of pain management therapy product

30 December 2016
Client work

Key contact(s):

Luke Kempton, Ian Piggin

Under the agreement, Astellas will transfer all of its commercialisation rights for Quenza to Grünenthal, and will continue to fully support the transition to ensure continuity of supply for those patients who rely on the drug. Qutenza is used for the treatment of peripheral neuropathic pain in adults.

Life Sciences partners Dr Luke Kempton and Ian Piggin worked on this complex sale.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences

Key contact(s)

Related Insights & Resources

View all insights Related Insights & Resources
Copyright and patent concept on computer screen Articles
26 March 2024 Trade secret tactics: 10 strategies for in-house counsel
Client work
18 March 2024 Capital Markets team advises on an equity fundraise to raise £9.9 million for AIM-listed, Oxford BioDynamics plc
Articles
12 February 2024 "Enforcing a provisional measure? Beware the revoked title!" CJEU assessed compliance with EU law of strict liability on the basis of a revoked title

Key contact(s)

Download or print PDF